Address
304 North Cardinal
St. Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM
Address
304 North Cardinal
St. Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM
Product Name: Prostaxen
Generic: Apalutamide
Strength: 60 mg
Each Pack Contains: 30 tablets
Indication: Metastatic and non-metastatic castration prostate cancer
Apalutamide 60 mg tablet (Prostaxen) is an FDA-approved androgen receptor inhibitor that was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer, and on September 17, 2019, for patients with metastatic castration-sensitive prostate cancer (mCSPC).
The brand name of this endrogen receptor inhibitor is ERLEADA, discovered and marketed by Janssen Biotech, Inc.
On the other hand, Prostaxen is a Bangladeshi-manufactured generic Apalutamide marketed by Everest Pharmaceuticals Ltd.
It is used to treat male adult patients with
Take 240 mg of Apalutamide tablets (4 tablets, each 60 mg) every day by mouth, with or without food, until disease progression or unacceptable toxicity occurs. Doctors may reduce the dose depending on the patient’s health condition or discontinue.
Patients who have taken Prostaxen 60 mg experienced these common effects in most cases
Based on animal studies, this medication may decrease reproductive capability in male patients.
Seizure occurred in patients who have been treated with this medication, and it is advised to stop the treatment permanently if a seizure occurs. It is not known if anti-epileptic medication can prevent seizure during the treatment.
Advise patients of the risk of developing seizure to be aware during the treatment of sudden loss of consciousness could harm themselves or others.
A fracture occurred in patients receiving the Prostaxen 60 mg tablet. Evaluate patients for fracture risk. Monitor and manage patients at risk of fracturing with established treatment guidelines.
According to the information from the FDA approval label, among patients with non-metastatic castration-resistant prostate cancer, the rate of fracture was 12%.
And patients with metastatic castration-resistant prostate cancer who received this medication, the fracture rate was 9%.
Some patients could suffer from some heart problems, like heart attacks, particularly if they have a previous history.
Any heart symptoms should be screened by your physician and controlled according to the routine of primary care for hypertensive, diabetic, and hyperlipidemic patients.
This medicine can affect how other drugs work by speeding up their breakdown in the body, making them less effective. If you are taking medicines that depend on specific enzymes or transporters, your doctor may need to adjust your treatment.
Extra care is needed if you use blood thinners like warfarin or similar drugs. Regular blood tests (INR) and dose monitoring are recommended to ensure safety.
Elimination of the drug alongside its active metabolite is assisted by CYP2C8. A strong CYP2C8 inhibitor such as gemfibrozil brought the peak concentration (Cmax) 21% lower, while overall exposure (AUC) was 68% greater.
Active constituents (drug plus active metabolite) of Cmax also AUC, both Cmax decreased by 21% and AUC increased by 45%. When administered with strong CYP2C8 inhibitors, no initial dose adjustment is required, but dose reduction may be necessary depending on patient tolerance.
It is expected that mild or moderate CYP2C8 inhibitors will have minimal impact on the drug’s levels.
CYP3A4 strong inhibitors, such as ketoconazole or ritonavir, do not change overall exposure but may lower peak levels.
No dose change is usually needed, though your doctor may make adjustments if side effects develop. Moderate and mild inhibitors do not have much to do little about the active.
Other medications metabolized by your body may have underlying effects as well. It may decrease the effects of drugs metabolized by CYP3A4, CYP2C19, CYP2C9, and UGT enzymes.
If these medications are used in combination, your physician may re-evaluate your medication plan or increase surveillance to check for a decrease in effects.
The cost of Apalutamide in Bangladesh depends on the manufacturer, dosage strength, and pharmacy source. It is generally considered a high-cost oncology medicine and is available through selected hospital pharmacies or authorized suppliers. The price may vary slightly between local and imported brands.
In regions such as the Middle East and Southeast Asia, including countries like Singapore, India, and China, Apalutamide is usually priced at a comparable or slightly higher level than in Bangladesh. Factors such as import duties, brand availability, and healthcare policies often influence the overall treatment cost.
Disclaimer: Information above is not for use as a medical advice alternative; always consult your doctor before taking any prescription medicines.
Reviews
There are no reviews yet.